Get the Facts: 2019 AUA/SUFU Diagnosis and Treatment of Non-Neurogenic OAB in Adults Guideline Update Webcast (2020)

Review and explore the recent changes to the 2019 AUA/SUFU Clinical Guideline on Diagnosis and Treatment of Non-Neurogenic OAB in Adults. Interactive, live interviews with subject matter experts will:

  • Explore the who, what, and why of this specific guideline update and how these changes will affect clinical practice. 
  • Provide first hand, clinical accounts that illustrate the proper application of these guidelines in day-to-day practice.
  • Demonstrate the importance of communicating proper patient expectations regarding treatment of OAB and maintaining a patient-centered focus. 

This webcast is part of a series of activities to be released by the AUA as part of an exciting new educational initiative entitled, Get the Facts: 2019 AUA/SUFU Diagnosis and Treatment of Non-Neurogenic OAB in Adults Guideline Update. The goal of this initiative is to update urologists and the urologic care team on the changes to the 2019 clinical guideline on Diagnosis and Treatment of Non-Neurogenic OAB in adults which discusses patient presentation, diagnosis, treatment and follow-up of patients based on the currently available data. The purpose of the guideline is to provide a clinical framework for the diagnosis and treatment of non-neurogenic OAB. 

This initiative is comprised of a variety of unique activities, including (3) live webinars - one each offered in English, Spanish and Portuguese. Each activity will be recorded and available in webcast format on AUAUniversity and AUA's YouTube channel. Additionally, the English version will be released as an episode on AUA's podcast. Faculty will promote clinical resources including the newly amended AUA/SUFU guideline available in English and Spanish, as well as the Portuguese translation of the abbreviated OAB guideline summary. Learners will also be provided with links to access OAB patient materials developed by the Urology Care Foundation to help facilitate the dialogue with their patients. 


This educational series is supported by an independent educational grant from:

  • Astellas 

Target Audience

  • Urologist
  • Resident
  • Advanced Practice Provider
  • Non-Urologist (MD or DO)
  • Nurse

Learning Objectives

At the conclusion of this activity, participants will be able to: 

  1. Define the similarities and differences between the various pharmacotherapies for OAB.
  2. Review the principles of physiology and pharmacotherapy for currently available agents, including the antimuscarinics and beta-3 agonists and combination therapy.
  3. Realize the importance of setting proper patient expectations regarding treatment of OAB and potential need for sequential and even additive therapies.
  4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.
  5. Discuss potential future pharmacological pathways and therapies for OAB. 


Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
Course expires: 

Education Council Disclosures

PDF iconEducation Council Disclosures

AUA Office of Education Staff has nothing to disclose.


Learners will participate in this online educational activity by viewing the webcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 1.00 hours

Release Date: February, 2020
Expiration Date: February, 2021


The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


The American Urological Association designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.


It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.


All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.


All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty


The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.